328 related articles for article (PubMed ID: 23551441)
1. The emerging role of histone deacetylase (HDAC) inhibitors in urological cancers.
Sharma NL; Groselj B; Hamdy FC; Kiltie AE
BJU Int; 2013 Apr; 111(4):537-42. PubMed ID: 23551441
[TBL] [Abstract][Full Text] [Related]
2. Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy.
Singh AK; Bishayee A; Pandey AK
Nutrients; 2018 Jun; 10(6):. PubMed ID: 29882797
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in histone deacetylase targeted cancer therapy.
Hoshino I; Matsubara H
Surg Today; 2010 Sep; 40(9):809-15. PubMed ID: 20740342
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic therapy of cancer with histone deacetylase inhibitors.
Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylases as targets in autoimmune and autoinflammatory diseases.
Hamminger P; Rica R; Ellmeier W
Adv Immunol; 2020; 147():1-59. PubMed ID: 32981634
[TBL] [Abstract][Full Text] [Related]
6. Targeting the Cancer Epigenome with Histone Deacetylase Inhibitors in Osteosarcoma.
Collier CD; Getty PJ; Greenfield EM
Adv Exp Med Biol; 2020; 1258():55-75. PubMed ID: 32767234
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic strategies to enhance the anticancer efficacy of histone deacetylase inhibitors.
Miller CP; Singh MM; Rivera-Del Valle N; Manton CA; Chandra J
J Biomed Biotechnol; 2011; 2011():514261. PubMed ID: 21765634
[TBL] [Abstract][Full Text] [Related]
8. HDACi--going through the mechanisms.
Wanczyk M; Roszczenko K; Marcinkiewicz K; Bojarczuk K; Kowara M; Winiarska M
Front Biosci (Landmark Ed); 2011 Jan; 16(1):340-59. PubMed ID: 21196174
[TBL] [Abstract][Full Text] [Related]
9. HDAC inhibitors as epigenetic regulators for cancer immunotherapy.
Conte M; De Palma R; Altucci L
Int J Biochem Cell Biol; 2018 May; 98():65-74. PubMed ID: 29535070
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase inhibitors in the treatment of hematological malignancies.
Petrella A; Fontanella B; Carratù A; Bizzarro V; Rodriquez M; Parente L
Mini Rev Med Chem; 2011 Jun; 11(6):519-27. PubMed ID: 21561404
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibitors for cancer therapy: An evolutionarily ancient resistance response may explain their limited success.
Halsall JA; Turner BM
Bioessays; 2016 Nov; 38(11):1102-1110. PubMed ID: 27717012
[TBL] [Abstract][Full Text] [Related]
12. Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials.
Qiu T; Zhou L; Zhu W; Wang T; Wang J; Shu Y; Liu P
Future Oncol; 2013 Feb; 9(2):255-69. PubMed ID: 23414475
[TBL] [Abstract][Full Text] [Related]
13. Histone Deacetylase Inhibitors Modulating Non-epigenetic Players: The Novel Mechanism for Small Molecule Based Therapeutic Intervention.
Ganai SA
Curr Drug Targets; 2018; 19(6):593-601. PubMed ID: 27231104
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylases and cancer-associated angiogenesis: current understanding of the biology and clinical perspectives.
Turtoi A; Peixoto P; Castronovo V; Bellahcène A
Crit Rev Oncog; 2015; 20(1-2):119-37. PubMed ID: 25746107
[TBL] [Abstract][Full Text] [Related]
15. Targeting Histone Deacetylases in Diseases: Where Are We?
Benedetti R; Conte M; Altucci L
Antioxid Redox Signal; 2015 Jul; 23(1):99-126. PubMed ID: 24382114
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylases and epigenetic therapies of hematological malignancies.
Mercurio C; Minucci S; Pelicci PG
Pharmacol Res; 2010 Jul; 62(1):18-34. PubMed ID: 20219679
[TBL] [Abstract][Full Text] [Related]
17. Advances in targeting histone deacetylase for treatment of solid tumors.
Shi MQ; Xu Y; Fu X; Pan DS; Lu XP; Xiao Y; Jiang YZ
J Hematol Oncol; 2024 May; 17(1):37. PubMed ID: 38822399
[TBL] [Abstract][Full Text] [Related]
18. An Overview of HDAC Inhibitors and their Synthetic Routes.
Peng X; Liao G; Sun P; Yu Z; Chen J
Curr Top Med Chem; 2019; 19(12):1005-1040. PubMed ID: 30827245
[TBL] [Abstract][Full Text] [Related]
19. Natural Agents-Mediated Targeting of Histone Deacetylases.
Farooqi AA; Naqvi SK; Perk AA; Yanar O; Tabassum S; Ahmad MS; Mansoor Q; Ashry MS; Ismail M; Naoum GE; Arafat WO
Arch Immunol Ther Exp (Warsz); 2018 Feb; 66(1):31-44. PubMed ID: 28852775
[TBL] [Abstract][Full Text] [Related]
20. Emerging role of histone deacetylase inhibitors as anti-breast-cancer agents.
Ediriweera MK; Tennekoon KH; Samarakoon SR
Drug Discov Today; 2019 Mar; 24(3):685-702. PubMed ID: 30776482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]